21:52 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

Actinium reports Phase II data for Actimab-A in AML

Actinium Pharmaceuticals Inc. (NYSE-M:ATNM) reported preliminary data from 13 evaluable patients ages 60 and older with newly diagnosed acute myelogenous leukemia (AML) who were unable to tolerate induction therapy in the Phase II portion of...
23:29 , Oct 6, 2017 |  BioCentury  |  Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
00:04 , Sep 22, 2017 |  BC Extra  |  Company News

Management tracks: Unity, Shield, Tusk

Anti-aging company Unity Biotechnology Inc. (San Francisco, Calif.) hired Bob Goeltz as CFO, Doug Rich as SVP of operations and Tamara Tompkins as general counsel. Goeltz will replace interim CFO John Smither, and Tompkins will...
19:53 , Aug 4, 2017 |  BC Week In Review  |  Financial News

Follow-on Roundup: Actinium, Kamada, Tetraphase

Immunotherapy play Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) and infectious disease company Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) each priced follow-on offerings, raising more than $96 million combined. Actinium raised $16.1...
23:20 , Jul 28, 2017 |  BC Extra  |  Financial News

Follow-on roundup: Actinium, Kamada, Tetraphase

Immunotherapy play Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) and infectious disease company Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) each priced follow-on offerings, raising more than $96 million combined. Actinium raised $16.1...
23:37 , Jun 9, 2017 |  BC Extra  |  Company News

Management tracks

The board of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) has recommended election of four new directors at its annual shareholder meeting on July 13. They are Murray Goldberg, a former SVP and CFO at...
21:56 , Feb 9, 2017 |  BC Week In Review  |  Clinical News

Actimab-M: Ph I started

Actinium began an open-label, U.S. Phase I trial to evaluate IV Actimab-M on day 1 of each 42-day cycle in about 12 patients. The starting dose of Actimab-M is 0.5 µCi/kg, which may be increased...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Reasonable rally

Steve Edelson, Senior Editor   It looks like biotech's rebound will continue through the end of the year, but not with enough gusto to match the third quarter, or to make up for losses in...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Actimab-A: Phase II started

Actinium began an open-label, U.S. Phase II trial to evaluate 2 uCi/kg/fraction doses of Actimab-A given at day 1 and 7 in about 53 patients ages >60. Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), New York, N.Y.  ...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Financial News

Actinium completes follow-on

Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), New York, N.Y.   Business: Cancer, Transplant   Date completed: 2016-09-29   Type: Follow-on   Raised: $10 million   Shares: 8 million   Price: $1.25   Shares after offering: 55.7 million...